CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of non-small cell lung cancer.
  
  LEARNING OBJECTIVES

  • Evaluate the various oncogenic alterations identifiable in the epidermal growth factor receptor (EGFR) tyrosine kinase domain, and determine how these may predict potential response or lack thereof to currently available EGFR-directed therapies.
  • Acknowledge the FDA approval of adjuvant osimertinib for localized non-small cell lung cancer (NSCLC) with an EGFR mutation, and identify patients for whom this novel approach would be warranted.
  • Evaluate published clinical trial findings supporting the use of osimertinib or erlotinib/ramucirumab as first-line therapy for patients with metastatic NSCLC and actionable EGFR mutations, and consider the implications of this information for clinical practice.
  • Develop an optimal therapeutic approach for patients with NSCLC with EGFR mutations and CNS metastases, considering symptomatology, number of lesions and other factors.
  • Describe mechanisms of tumor resistance to EGFR tyrosine kinase inhibitors (TKIs), and discern how available and investigational therapies can be optimally employed in the protocol and nonresearch care of patients with progressive NSCLC with EGFR mutations.
  • Evaluate the mechanism of action of and published research data with the dual-targeting EGFR-MET bispecific antibody amivantamab and the novel EGFR TKI mobocertinib for NSCLC with an EGFR exon 20 insertion mutation, and consider how these therapies fit into current clinical management algorithms.
  • Recall the biologic rationale for the design of ongoing clinical trials evaluating novel therapeutic approaches for patients with NSCLC with EGFR mutations.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  HOW TO USE THIS CME ACTIVITY
  This CME activity consists of an audio component.
  CME credit is no longer available for this issue
  
  This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
  
  Pasi A Jänne, MD, PhD
  Director, Lowe Center for Thoracic Oncology
  Professor of Medicine, Harvard Medical School
  Director, Robert and Renée Belfer Center for Applied Cancer Sciences
  Director, Chen-Huang Center for EGFR-Mutant Lung Cancers
  Dana-Farber Cancer Institute
  Boston, Massachusetts
  
  Consulting Agreements: AbbVie Inc, ACEA Biosciences Inc, Accutar Biotech, Allorion Therapeutics, Araxes Pharma, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biocartis, Boehringer Ingelheim Pharmaceuticals Inc, Chugai Pharmaceutical Co Ltd, Daiichi Sankyo Inc, Eisai Inc, Genentech, a member of the Roche Group, Ignyta Inc, Kura Oncology, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Mirati Therapeutics Inc, Novartis, Nuvalent, Pfizer Inc, Sanofi, SFJ Pharmaceuticals, Silicon Therapeutics, Syndax Pharmaceuticals Inc, Takeda Pharmaceuticals USA Inc, Transcenta, Voronoi; Contracted Research: Astellas, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Daiichi Sankyo Inc, Lilly, Puma Biotechnology Inc, Revolution Medicines, Takeda Pharmaceuticals USA Inc; Nonrelevant Financial Relationship: Labcorp for postmarketing royalties from Dana-Farber Cancer Institute-owned intellectual property on EGFR mutations licensed to Labcorp.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  These activities are supported by educational grants from AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, and Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC.
  
  Release date: October 2022
  Expiration date: October 2023